Table 6.
Fatty acid composition (µg/ml) in plasma at baseline and after 12 weeks of intervention (Medians and 25th–75th percentiles)
| High ALA-DAG (n 10) | High ALA-TAG (n 13) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | End of study | Baseline | End of study | ||||||||
| Median | 25th–75th percentiles | Median | 25th–75th percentiles | P* | Median | 25th–75th percentiles | Median | 25th–75th percentiles | P† | P‡ | |
| 14 : 0 | 25·8 | 21·4–32·4 | 25·1 | 20·2–31·7 | 0·8 | 33·0 | 22·8–40·3 | 33·2 | 27·1–45·8 | 0·9 | 0·7 |
| 15 : 0 | 5·9 | 5·1–6·7 | 6·1 | 4·7–6·6 | 0·7 | 6·4 | 5·3–7·5 | 6·7 | 5·3–7·8 | 0·7 | 0·6 |
| 16 : 0 | 690·7 | 607·0–802·4 | 691·5 | 570·0–754·1 | 0·4 | 741·3 | 655·6–891·5 | 789·1 | 689·2–877·8 | 0·6 | 0·2 |
| 18 : 0 | 233·8 | 196·5–252·4 | 216·8 | 199·7–228·9 | 0·06 | 250·2 | 206·1–274·1 | 253·8 | 202·8–278·9 | 0·8 | 0·1 |
| 20 : 0 | 8·3 | 6·8–9·3 | 8·4 | 6·9–8·9 | 0·6 | 8·2 | 7·4–9·8 | 9·1 | 8·1–9·9 | 0·2 | 0·1 |
| 22 : 0 | 31·3 | 23·5–32·6 | 27·5 | 23·2–28·7 | 0·03 | 24·9 | 23·1–29·8 | 25·6 | 21·0–27·4 | 0·3 | 0·1 |
| 23 : 0 | 10·8 | 9·0–12·6 | 10·0 | 9·3–13·1 | 0·7 | 9·3 | 8·9–11·0 | 10·7 | 9·0–11·5 | 0·1 | 0·2 |
| 24 : 0 | 30·3 | 23·7–33·1 | 28·4 | 22·8–31·0 | 0·07 | 26·8 | 22·9–28·8 | 26·7 | 22·0–29·8 | 0·9 | 0·06 |
| 16 : 1 | 50·2 | 45·1–68·1 | 49·4 | 42·6–65·7 | 1·0 | 57·0 | 39·7–85·9 | 69·6 | 54·0–86·2 | 0·2 | 0·2 |
| 18 : 1t-6-11 | 7·9 | 6·7–9·6 | 9·1 | 6·7–9·9 | 1·0 | 9·9 | 7·2–11·2 | 9·7 | 8·5–12·9 | 0·7 | 0·7 |
| 18 : 1c-9 | 595·8 | 517·9–790·3 | 594·5 | 515·2–723·4 | 0·6 | 625·6 | 500·8–765·8 | 776·8 | 681·0–798·9 | 0·06 | 0·03 |
| 18 : 1c-11 | 44·7 | 41·0–52·7 | 42·5 | 41·0–54·5 | 1·0 | 46·5 | 36·9–57·1 | 52·0 | 45·0–60·7 | 0·04 | 0·04 |
| 24 : 1n-9 | 41·4 | 34·9–46·8 | 39·8 | 39·2–53·8 | 0·07 | 38·0 | 33·8–44·9 | 42·2 | 38·9–46·0 | 0·1 | 0·7 |
| 18 : 3n-3 | 23·0 | 20·0–32·2 | 48·6 | 39·9–62·2 | 0·005 | 24·9 | 21·2–28·3 | 58·3 | 49·5–84·9 | 0·002 | 0·04 |
| 20 : 5n-3 | 35·8 | 24·4–67·8 | 57·0 | 38·9–91·5 | 0·04 | 28·0 | 22·7–64·7 | 56·5 | 40·5–76·7 | 0·02 | 0·8 |
| 22 : 5n-3 | 18·7 | 17·0–25·7 | 20·8 | 18·9–24·6 | 0·7 | 21·1 | 18·5–24·3 | 25·9 | 22·3–29·2 | 0·007 | 0·3 |
| 22 : 6n-3 | 106·3 | 79·1–136·7 | 87·8 | 72·1–110·7 | 0·1 | 90·1 | 76·3–129·1 | 93·9 | 69·0–129·6 | 0·2 | 0·6 |
| 18 : 2n-6 | 1128·5 | 995·7–1223·8 | 936·8 | 857·4–1141·0 | 0·03 | 1088·0 | 1018·2–1234·3 | 984·1 | 924·3–1202·0 | 0·03 | 0·4 |
| 18 : 3n-6 | 14·2 | 13·0–18·4 | 10·8 | 8·3–15·0 | 0·09 | 18·4 | 14·1–21·1 | 14·3 | 9·8–21·3 | 0·3 | 0·7 |
| 20 : 2n-6 | 9·6 | 8·4–11·4 | 8·6 | 6·9–10·1 | 0·02 | 10·1 | 9·0–12·9 | 10·9 | 8·8–11·6 | 0·9 | 0·1 |
| 20 : 3n-6 | 51·9 | 37·7–64·4 | 39·2 | 32·1–45·8 | 0·007 | 53·3 | 39·1–64·1 | 42·1 | 35·3–56·8 | 0·1 | 0·4 |
| 20 : 4n-6 | 210·7 | 171·0–230·2 | 188·7 | 146·5–209·2 | 0·06 | 201·9 | 168·3–213·1 | 206·5 | 164·7–217·1 | 0·5 | 0·05 |
| 22 : 4n-6 | 4·6 | 4·0–6·3 | 4·3 | 3·3–4·9 | 0·02 | 5·4 | 5·1–6·7 | 5·6 | 4·4–6·3 | 0·5 | 0·2 |
| 22 : 5n-6 | 12·9 | 10·1–13·9 | 12·1 | 11·0–13·1 | 0·7 | 11·7 | 11·1–13·6 | 11·8 | 10·4–14·3 | 0·9 | 0·5 |
ALA, α-linolenic acid; DAG, diacylglycerol.
* Within the high-ALA-DAG group (prior to Bonferroni correction).
† Within the high-ALA-TAG group (prior to Bonferroni correction).
‡ Comparing change from baseline to the end of the study between the high-ALA-DAG and high-ALA-TAG groups (prior to Bonferroni correction).